Lung Cancer Dispatch
Follow
Find tag "Avastin"
4.3K views | +0 today
Lung Cancer Dispatch
News for Patients and Physicians
Curated by Cancer Commons
Your new post is loading...
Your new post is loading...
Scooped by Cancer Commons
Scoop.it!

ASCO: Targeted Tx Combo Stalls NSCLC

ASCO: Targeted Tx Combo Stalls NSCLC | Lung Cancer Dispatch | Scoop.it

"Adding bevacizumab (Avastin) to first-line targeted therapy delayed progression in a subgroup of non-small cell lung cancer (NSCLC), an open-label trial showed.


"Progression-free survival was 46% better with bevacizumab plus erlotinib (Tarceva), at 16.0 months compared with 9.7 on erlotinib alone in an EGFR mutation-positive population (P=0.0015), Terufumi Kato, MD, of Kanagawa Cardiovascular and Respiratory Center in Yokohama, Japan, and colleagues found."


Editor's note: A combination of two targeted therapy drugs has shown promise for treating some patients with non-small cell lung cancer (NSCLC). The two drugs are called bevacizumab (brand name Avastin) and erlotinib (brand name Tarceva). The research described in this story found that the combination works better for patients whose tumors have mutations in the EGFR gene (as detected by molecular testing) than erlotinib alone.

Cancer Commons's insight:

MedPage Today  |  Jun 3, 2014

more...
No comment yet.
Suggested by Cancer Commons
Scoop.it!

Four-Drug Combination Shown to Be Safe and Effective for NSCLC

Four-Drug Combination Shown to Be Safe and Effective for NSCLC | Lung Cancer Dispatch | Scoop.it

A combination of the drugs carboplatin (Paraplatin), paclitaxel (Taxol/Abraxane), cetuximab (Erbitux), and bevacizumab (Avastin) has demonstrated effectiveness against non-small cell lung cancer (NSCLC) in a phase II clinical trial. One hundred two patients with advanced non-squamous NSCLC received the four-drug combo as a first-line treatment. Tumors shrank in 56% of patients and stopped growing in an additional 21%. Patients went an average of 7 months without their cancer progressing; the average survival time was 15 months. Four treatment-related deaths occurred, including two due to hemorrhage (heavy bleeding), which can be a rare but serious effect of Avastin treatment. This side effect profile was within the predefined safety margin. A phase III trial further investigating this drug combination for NSCLC is currently enrolling participants.

Cancer Commons's insight:

MedwireNews  |  Dec 2, 2013

more...
No comment yet.
Suggested by Cancer Commons
Scoop.it!

Alimta Offers Only Limited Advantage in Lung Cancer Study

The recent PointBreak clinical trial compared two treatment regimens for non-squamous non-small cell lung cancer (NSCLC). Previously untreated patients with advanced non-squamous NSCLC received initial treatment with carboplatin (Paraplatin), bevacizumab (Avastin), and either pemetrexed (Alimta) or paclitaxel (Taxol/Abraxane). The Alimta-treated group was then given maintenance treatment with Alimta and Avastin, while the other patients received Avastin only. Alimta treatment was associated with slightly longer times until the cancer progressed again (average 6.0 months, compared to 5.6 in the Alimta-free regimen). However, overall survival did not differ between the groups. The two regimens differed in what specific side effect were most common, but had similar overall toxicities and were generally tolerable.

Cancer Commons's insight:

MedPage Today | Oct 21, 2013

more...
No comment yet.
Suggested by Cancer Commons
Scoop.it!

Maintenance Therapy with Avastin-Alimta Combination Appears Effective in Advanced NSCLC

Maintenance Therapy with Avastin-Alimta Combination Appears Effective in Advanced NSCLC | Lung Cancer Dispatch | Scoop.it

Maintenance therapy with bevacizumab (Avastin) and pemetrexed (Alimta) showed promising effects in the AVAPERL phase III clinical trial. Patients with advanced non-small cell lung cancer (NSCLC) were first treated with Avastin, Alimta, and cisplatin (Platinol). Those who responded to the treatment were either continued on both Avastin and Alimta or on Avastin only. Patients maintained on both drugs experienced more serious side effects, but went for longer without their cancer progressing (7.4 months on average, compared to 3.7 months for Avastin-only patients). While the study did not examine the benefits of Alimta-only maintenance treatment, the results suggest that the Avastin-Alimta combination is preferable to maintenance on Avastin only.

Cancer Commons's insight:

Healio | Jul 26, 2013

more...
No comment yet.
Suggested by Cancer Commons
Scoop.it!

Bone and Brain Metastases Are Common in Lung Cancer, But Avastin May Lower Risk

Lung cancer patients often develop metastases (cancer that has spread) in their bones or brain. A retrospective study of non-small cell lung cancer (NSCLC) patients with metastases revealed that in 39%, the cancer spread affected the bones, and in 30% the spread affected the brain. Bone metastases were more common in elderly patients, were linked to skeletal complications, such as fractures, and were associated with shorter survival (5.5 months vs 9.9 months in patients without bone metastases). Another study found that NSCLC patients who developed new bone metastases were more likely to get brain metastases also. However, patients treated with bevacizumab (Avastin) were less prone to metastases in either the bones (27% vs 43% without Avastin) or the brain (25% vs 33%).

Cancer Commons's insight:

Cancer Network | Jul 8, 2013

more...
No comment yet.
Suggested by Cancer Commons
Scoop.it!

Gene Variations May Predict Outcomes in Non-Small Cell Lung Cancer

Gene Variations May Predict Outcomes in Non-Small Cell Lung Cancer | Lung Cancer Dispatch | Scoop.it

Variations in two genes called CXCR-2 and PAR-1 may predict how a person with non-small cell lung cancer (NSCLC) will fare. A study of over 200 NSCLC patients found that those with certain versions of the genes were likely to experience faster disease progression and shorter survival, especially if patients had squamous cell carcinoma (SCC). Both genes are involved in tumor angiogenesis, that is, the growth of new blood vessels that enable tumors to expand. In the future, testing for these high-risk gene variants may help identify good candidates for anti-angiogenesis treatments like bevacizumab (Avastin).

Cancer Commons's insight:

Lung Cancer | Mar 30, 2013

more...
No comment yet.
Suggested by Cancer Commons
Scoop.it!

Phase II Trial of Lung Cancer Drug Imprime PGG Completes Patient Enrollment

Biothera has completed patient enrollment in a second phase II clinical trial testing a drug called Imprime PGG against non-small cell lung cancer (NSCLC). Imprime PGG redirects the immune system to attack the cancer. The drug also enhances the effectiveness of antibody drugs (drugs in the form of a type of immune system protein) like bevacizumab (Avastin) or cetuximab (Erbitux). The current phase II trial will compare NSCLC patients receiving Imprime PGG in combination with Avastin and chemotherapy to those receiving only Avastin and chemotherapy. Another ongoing phase II trial uses a similar design, but with Erbitux instead of Avastin, and has produced promising preliminary results.

Cancer Commons's insight:

Reuters | Mar 13, 2013

more...
No comment yet.
Suggested by Cancer Commons
Scoop.it!

Avastin-Taxol Regimen May Be Effective Late-Line Treatment for Advanced Non-Squamous NSCLC

Avastin-Taxol Regimen May Be Effective Late-Line Treatment for Advanced Non-Squamous NSCLC | Lung Cancer Dispatch | Scoop.it

A retrospective study assessed the use of weekly bevacizumab (Avastin) along with paclitaxel (Taxol) every 3 weeks in patients with advanced non-squamous, non-small cell lung cancer (NSCLC) who had previously received at least three rounds of treatment. The Avastin-Taxol combination was found to be an effective anti-tumor treatment. Some patients experienced serious side effects, including one death. However, overall toxicity was deemed acceptable compared to typical chemotherapy results in similar patients.

Cancer Commons's insight:

Lung Cancer | Feb 14, 2013

more...
No comment yet.
Suggested by Cancer Commons
Scoop.it!

Lung Cancer Drug BGB324 May Counteract Drug Resistance

Lung Cancer Drug BGB324 May Counteract Drug Resistance | Lung Cancer Dispatch | Scoop.it

The protein Axl has been associated with cell transformation processes that contribute to the spread of cancer through the body and to cancers becoming drug resistant. A recent study investigated the effect of the Axl inhibitor BGB324 on non-small cell lung cancer (NSCLC) cells that had become resistant to EGFR inhibitors like erlotinib (Tarceva). BGB324 restored the effectiveness of EGFR inhibitors against these cancer cells, which had been grown either in a matrix or as tumors in mice. BGB324 also appeared to enhance the effectiveness of the chemotherapy drug docetaxel (Taxotere) and of bevacizumab (Avastin). BGB324 may therefore be a promising new candidate for treating drug-resistant NSCLC. The drug will be tested in a phase Ib clinical trial for NSCLC in 2014.

Cancer Commons's insight:

Medical News Today  |  Jan 13, 2014

more...
No comment yet.
Suggested by Cancer Commons
Scoop.it!

Erbitux-Avastin Combination Plus Chemotherapy in Lung Cancer Is Safe and Effective

Erbitux-Avastin Combination Plus Chemotherapy in Lung Cancer Is Safe and Effective | Lung Cancer Dispatch | Scoop.it

Combining cetuximab (Erbitux), bevacizumab (Avastin), and traditional chemotherapy in patients with non-small cell lung cancer (NSCLC) appeared to be safe and effective in a phase II clinical trial. Patients with advanced non-squamous NSCLC received Erbitux and Avastin in addition to carboplatin (Paraplatin) and paclitaxel (Taxol/Abraxane) as first-line treatment, followed by maintenance treatment with Erbitux and Avastin. Tumors shrank in 56% of patients and stopped growing in an additional 21%. Serious side effects were relatively rare; the rate was comparable to that of either Erbitux or Avastin alone. Both Erbitux and Avastin have shown efficacy in NSCLC by themselves, but may be more effective when given together. An ongoing phase III clinical trial will further investigate this drug combination.

Cancer Commons's insight:

Medical News Today | Nov 5, 2013

more...
No comment yet.
Suggested by Cancer Commons
Scoop.it!

Adding Tarceva to Avastin Maintenance Therapy Does Not Increase Lung Cancer Survival

Adding Tarceva to Avastin Maintenance Therapy Does Not Increase Lung Cancer Survival | Lung Cancer Dispatch | Scoop.it

Results from the ATLAS clinical trial indicate that adding erlotinib (Tarceva) to maintenance therapy with bevacizumab (Avastin) does not increase survival in non-small cell lung cancer (NSCLC). Patients with advanced NSCLC who had been successfully treated with chemotherapy and Avastin received continued treatment with Avastin plus either Tarceva or a placebo. In patients who received both Avastin and Tarceva, the cancer took longer to start progressing again than in the patients given only Avastin (4.8 vs 3.7 mo, on average), but overall survival was not significantly different. Moreover, patients treated with both Tarceva and Avastin experienced more side effects. However, the benefits of added Tarceva were greater in the subgroup of patients with mutations in the EGFR gene.

Cancer Commons's insight:

MedPage Today | Oct 7, 2013

more...
No comment yet.
Suggested by Cancer Commons
Scoop.it!

Diagnostics Company Ready to Patent Test for Squamous Cell Lung Cancer

Diagnostics Company Ready to Patent Test for Squamous Cell Lung Cancer | Lung Cancer Dispatch | Scoop.it

The molecular diagnostics company Rosetta Genomics has received permission to patent their Rosetta Lung Cancer Test. The test analyzes lung tumor tissue and distinguishes squamous cell carcinoma (SCC) from other types of non-small cell lung cancer (NSCLC). Clearly identifying a patient's cancer subtype is becoming increasingly important for choosing an optimal treatment plan, thanks to the increasing role of targeted therapies and the growing understanding of how drug effects can differ among various cancer subtypes. For example, pemetrexed (Alimta) and bevacizumab (Avastin) benefit many NSCLC patients, but are not recommended for those with SCC. The patent allowance will permit Rosetta to develop their test for use in patients.

Cancer Commons's insight:

Yahoo! Finance | Jul 25, 2013

more...
No comment yet.
Suggested by Cancer Commons
Scoop.it!

Comparison of Combination Chemotherapy Regimens Shows No Significant Differences

Both pemetrexed (Alimta) plus carboplatin (Paraplatin) and Paraplatin plus paclitaxel (Taxol/Abraxane) plus bevacizumab (Avastin) are effective chemotherapy regimens against non-small cell lung cancer (NSCLC). However, until recently, the safety and efficacy of the two regimens had not been directly compared. To evaluate whether one regimen was superior, a phase III clinical trial determined how long patients with advanced non-squamous NSCLC remained free of either cancer progression or severe toxic side effects when treated with either of the two regimens. While patients receiving the Alimta plus Paraplatin regimen tended to have slightly longer relapse- and toxicity-free periods than those given Paraplatin plus Taxol/Abraxane plus Avastin, the difference was not very pronounced and could have happened by chance. The two regimens also did not differ regarding overall time until cancer progression, response rate and overall survival time.

Cancer Commons's insight:

CancerNetwork | June 6, 2013

more...
No comment yet.
Suggested by Cancer Commons
Scoop.it!

Avastin May Be Effective Against Lung Cancer with Bone Metastases

A retrospective study of cancer patients suggests that bevacizumab (Avastin) may be an effective treatment for non-small cell lung cancer (NSCLC) with bone metastases (cancer spread to the bone). The patients had non-squamous NSCLC with bone metastases and had been treated with zoledronic acid (Zometa/Reclast) and chemotherapy either with or without Avastin. Avastin treatment was associated with better control of both bone metastases and overall disease, longer time to bone metastasis progression, and fewer complications related to bone degeneration, such as fractures or spinal cord compression. Research paper: http://link.springer.com/article/10.1007%2Fs00280-013-2148-3

Cancer Commons's insight:

Cancer Chemotherapy and Pharmacology  | Mar 27, 2013

more...
No comment yet.
Suggested by Cancer Commons
Scoop.it!

Tarceva May Be More Effective in Advanced NSCLC When Combined with Other Targeted Therapies

Tarceva May Be More Effective in Advanced NSCLC When Combined with Other Targeted Therapies | Lung Cancer Dispatch | Scoop.it

An analysis of multiple clinical trials compared erlotinib (Tarceva) alone to combining Tarceva with other targeted therapies as second-line treatment for advanced non-small cell lung cancer (NSCLC). In the various trials, Tarceva was combined with bevacizumab (Avastin), bortezomib (Velcade), everolimus (Afinitor), sorafenib (Nexavar), sunitinib (Sutent), entinostat, tivantinib, and R1507. While combined therapy produced more side effects, it was more effective than Tarceva alone. Notably, the trials included many patients who had not been tested for mutations in the EGFR and KRAS genes. In patients who had EGFR mutations and/or lacked KRAS mutations, Tarceva alone tended to control cancer progression better than combined therapy, highlighting the importance of biomarker testing to identify which patients are most likely to benefit from different therapies.

Cancer Commons's insight:

PLoS ONE | Feb 8, 2013

more...
No comment yet.
Scooped by Cancer Commons
Scoop.it!

Avastin-Containing Chemotherapy May be Safe in Lung Cancer Patients with Brain Metastases

Bevacizumab (Avastin), which is approved for treatment of a number of advanced-stage cancer types, is commonly avoided in patients with brain metastases (cancer that has spread to the brain) because of fear of brain hemorrhages (bleeding in the brain). A retrospective study of 52 patients with advanced non-small cell lung cancer (NSCLC) who had received chemotherapy containing Avastin found no cases of serious bleeding events and no significant differences in survival or treatment side effects between patients with or without brain metastases. Avastin may therefore be a safe treatment option in NSCLC with brain metastases.

 

Research paper: https://www.jstage.jst.go.jp/article/acrt/20/2/20_47/_pdf

Cancer Commons's insight:

Annals of Cancer Research and Therapy | Sep 28, 2012

more...
No comment yet.